Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Significance of Beta-Blocker in Patients with Hypertensive Left Ventricular Hypertrophy and Myocardial Ischemia

Author(s): Goran Koracevic, Slađana Mićić, Milovan Stojanovic*, Nenad Bozinovic, Dragan Simic, Dragan Lović, Nebojsa Krstic and Ružica Janković Tomašević

Volume 21, Issue 2, 2023

Published on: 24 February, 2023

Page: [81 - 90] Pages: 10

DOI: 10.2174/1570161121666230201141215

Price: $65

Abstract

Background: Arterial Hypertension (HTN) is a key risk factor for left ventricular hypertrophy (LVH) and a cause of ischemic heart disease (IHD). The association between myocardial ischemia and HTN LVH is strong because myocardial ischemia can occur in HTN LVH even in the absence of significant stenoses of epicardial coronary arteries.

Objective: To analyze pathophysiological characteristics/co-morbidities precipitating myocardial ischemia in patients with HTN LVH and provide a rationale for recommending beta-blockers (BBs) to prevent/treat ischemia in LVH.

Methods: We searched PubMed, SCOPUS, PubMed, Elsevier, Springer Verlag, and Google Scholar for review articles and guidelines on hypertension from 01/01/2000 until 01/05/2022. The search was limited to publications written in English.

Results: HTN LVH worsens ischemia in coronary artery disease (CAD) patients. Even without obstructive CAD, several pathophysiological mechanisms in HTN LVH can lead to myocardial ischemia. In the same guidelines that recommend BBs for patients with HTN and CAD, we could not find a single recommendation for BBs in patients with HTN LVH but without proven CAD. There are several reasons for the proposal of using some BBs to control ischemia in patients with HTN and LVH (even in the absence of obstructive CAD).

Conclusion: Some BBs ought to be considered to prevent/treat ischemia in patients with HTN LVH (even in the absence of obstructive CAD). Furthermore, LVH and ischemic events are important causes of ventricular tachycardia, ventricular fibrillation, and sudden cardiac death; these events are another reason for recommending certain BBs for HTN LVH.

Keywords: Coronary artery disease, myocardial ischemia, arterial hypertension, beta-blockers, sudden cardiac death, ventricular tachycardia, ventricular fibrillation, left ventricular hypertrophy.

« Previous
Graphical Abstract

[1]
Williams B, Mancia G, Spiering W, et al. ESC scientific document group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[2]
Tadic M, Cuspidi C, Grassi G. The influence of sex on left ventricular remodeling in arterial hypertension. Heart Fail Rev 2019; 24(6): 905-14.
[http://dx.doi.org/10.1007/s10741-019-09803-3] [PMID: 31076937]
[3]
Cuspidi C, Rescaldani M, Sala C, Negri F, Grassi G, Mancia G. Prevalence of electrocardiographic left ventricular hypertrophy in human hypertension. J Hypertens 2012; 30(11): 2066-73.
[http://dx.doi.org/10.1097/HJH.0b013e32835726a3] [PMID: 22914541]
[4]
Woodiwiss AJ, Norton GR. Obesity and left ventricular hypertrophy: the hypertension connection. Curr Hypertens Rep 2015; 17(4): 28.
[http://dx.doi.org/10.1007/s11906-015-0539-z] [PMID: 25794954]
[5]
Stewart MH, Lavie CJ, Shah S, et al. Prognostic implications of left ventricular hypertrophy. Prog Cardiovasc Dis 2018; 61(5-6): 446-55.
[http://dx.doi.org/10.1016/j.pcad.2018.11.002] [PMID: 30408469]
[6]
Palatini P, Saladini F, Mos L, et al. Obesity is a strong determinant of hypertensive target organ damage in young-to-middle-age patients. Int J Obes 2013; 37(2): 224-9.
[http://dx.doi.org/10.1038/ijo.2012.32] [PMID: 22391882]
[7]
Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273(20): 1592-7.
[http://dx.doi.org/10.1001/jama.1995.03520440046035] [PMID: 7745772]
[8]
Unger T, Borghi C, Charchar F, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension 2020; 75(6): 1334-57.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.15026] [PMID: 32370572]
[9]
Tackling G, Borhade MB. Hypertensive Heart Disease. Treasure Island, FL: StatPearls Publishing 2021.
[10]
Hatano Y, Yano Y, Fujimoto S, et al. The population-attributable fraction for premature mortality due to cardiovascular disease associated with stage 1 and 2 hypertension among Japanese. Am J Hypertens 2021; 34(1): 56-63.
[http://dx.doi.org/10.1093/ajh/hpaa128] [PMID: 32756946]
[11]
Koracevic G, Stojanovic M, Kostic T, Lovic D, Tomasevic M, Jankovic-Tomasevic R. Unsolved problem: (Isolated) Systolic hypertension with diastolic blood pressure below the safety margin. Med Princ Pract 2020; 29(4): 301-9.
[http://dx.doi.org/10.1159/000508462] [PMID: 32380500]
[12]
Lip GYH, Coca A, Kahan T, et al. Hypertension and cardiac arrhythmias: Executive summary of a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Eur Heart J Cardiovasc Pharmacother 2017; 3(4): 235-50.
[http://dx.doi.org/10.1093/ehjcvp/pvx019] [PMID: 28541499]
[13]
Jalali S, Wohlin C. Systematic literature studies: database searches vs. backward snowballing. In: ESEM 12 Conference Committee, Eds ESEM '12 Proceedings of the ACM-IEEE international symposium on Empirical software engineering and measurement 1st ed. New York: Association for Computing Machinery 2012; pp. 29-38.
[http://dx.doi.org/10.1145/2372251.2372257]
[14]
Stanton T, Dunn FG. Hypertension, left ventricular hypertrophy, and myocardial ischemia. Med Clin North Am 2017; 101(1): 29-41.
[http://dx.doi.org/10.1016/j.mcna.2016.08.003] [PMID: 27884233]
[15]
Roever L, Pinto IM, Chagas ACP. The association of left ventricular mass with coronary atherosclerosis and myocardial ischemia: cause and effect or simple association? Eur Heart J Cardiovasc Imag 2015; 16(2): 156-7.
[http://dx.doi.org/10.1093/ehjci/jeu221] [PMID: 25381302]
[16]
Kishi S, Magalhaes TA, George RT, et al. Relationship of left ventricular mass to coronary atherosclerosis and myocardial ischaemia: the CORE320 multicenter study. Eur Heart J Cardiovasc Imag 2015; 16(2): 166-76.
[http://dx.doi.org/10.1093/ehjci/jeu217] [PMID: 25368207]
[17]
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110(2): 101-7.
[http://dx.doi.org/10.7326/0003-4819-110-2-101] [PMID: 2521199]
[18]
Cooper RS, Simmons BE, Castaner A, Santhanam V, Ghali J, Mar M. Left ventricular hypertrophy is associated with worse survival independent of ventricular function and number of coronary arteries severely narrowed. Am J Cardiol 1990; 65(7): 441-5.
[http://dx.doi.org/10.1016/0002-9149(90)90807-D] [PMID: 2137665]
[19]
Lang RM, Bierig M, Devereux RB, et al. Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18(12): 1440-63.
[http://dx.doi.org/10.1016/j.echo.2005.10.005] [PMID: 16376782]
[20]
Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31(7): 1635-40.
[http://dx.doi.org/10.1016/S0735-1097(98)00131-4] [PMID: 9626845]
[21]
Truong QA, Toepker M, Mahabadi AA, et al. Relation of left ventricular mass and concentric remodeling to extent of coronary artery disease by computed tomography in patients without left ventricular hypertrophy: ROMICAT study. J Hypertens 2009; 27(12): 2472-82.
[http://dx.doi.org/10.1097/HJH.0b013e328331054a] [PMID: 19696685]
[22]
Lin FY, Nicolo D, Devereux RB, et al. Nonobstructive coronary artery disease as detected by 64-detector row cardiac computed tomographic angiography is associated with increased left ventricular mass. J Cardiovasc Comput Tomogr 2011; 5(3): 158-64.
[http://dx.doi.org/10.1016/j.jcct.2011.01.006] [PMID: 21376693]
[23]
Grossman C, Levin M, Koren-Morag N, et al. Left ventricular hypertrophy predicts cardiovascular events in hypertensive patients with coronary artery calcifications. Am J Hypertens 2018; 31(3): 313-20.
[http://dx.doi.org/10.1093/ajh/hpx181] [PMID: 29036433]
[24]
Stewart MG. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet 1979; 313(8121): 861-5.
[http://dx.doi.org/10.1016/S0140-6736(79)91274-1] [PMID: 86103]
[25]
Altunkan S, Erdogan N, Altin L, Budoff MJ. Relation of coronary artery calcium to left ventricular mass and geometry in patients with essential hypertension. Blood Press Monit 2003; 8(1): 9-15.
[http://dx.doi.org/10.1097/00126097-200302000-00002] [PMID: 12604929]
[26]
Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140(6): 848-56.
[http://dx.doi.org/10.1067/mhj.2000.111112] [PMID: 11099987]
[27]
Chen G, Levy D. Contributions of the framingham heart study to the epidemiology of coronary heart disease. JAMA Cardiol 2016; 1(7): 825-30.
[http://dx.doi.org/10.1001/jamacardio.2016.2050] [PMID: 27464224]
[28]
Aronow WS. Hypertension and left ventricular hypertrophy. Ann Transl Med 2017; 5(15): 310.
[http://dx.doi.org/10.21037/atm.2017.06.14] [PMID: 28856150]
[29]
Messerli FH, Panjrath GS. The J-curve between blood pressure and coronary artery disease or essential hypertension: exactly how essential? J Am Coll Cardiol 2009; 54(20): 1827-34.
[http://dx.doi.org/10.1016/j.jacc.2009.05.073] [PMID: 19892233]
[30]
McEvoy JW, Chen Y, Rawlings A, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol 2016; 68(16): 1713-22.
[http://dx.doi.org/10.1016/j.jacc.2016.07.754] [PMID: 27590090]
[31]
Escobar E. Hypertension and coronary heart disease. J Hum Hypertens 2002; 16 (Suppl. 1): S61-3.
[http://dx.doi.org/10.1038/sj.jhh.1001345] [PMID: 11986897]
[32]
Nwabuo CC, Vasan RS. Pathophysiology of hypertensive heart disease: Beyond left ventricular hypertrophy. Curr Hypertens Rep 2020; 22(2): 11.
[http://dx.doi.org/10.1007/s11906-020-1017-9] [PMID: 32016791]
[33]
Cunningham KS, Spears DA, Care M. Evaluation of cardiac hypertrophy in the setting of sudden cardiac death. Forensic Sci Res 2019; 4(3): 223-40.
[http://dx.doi.org/10.1080/20961790.2019.1633761] [PMID: 31489388]
[34]
Brown JM, Zhou W, Weber B, et al. Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease. Eur Heart J 2021; 2021: ehab610.
[PMID: 34491335]
[35]
Sultana R, Sultana N, Rashid A, et al. Cardiac arrhythmias and left ventricular hypertrophy in systemic hypertension. J Ayub Med Coll Abbottabad 2010; 22(4): 155-8.
[PMID: 22455286]
[36]
Weber T, Lang I, Zweiker R, et al. Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations. Wien Klin Wochenschr 2016; 128(13-14): 467-79.
[http://dx.doi.org/10.1007/s00508-016-0998-5] [PMID: 27278135]
[37]
Eskerud I, Gerdts E, Larsen TH, Lønnebakken MT. Left ventricular hypertrophy contributes to myocardial ischemia in non-obstructive coronary artery disease (the MicroCAD study). Int J Cardiol 2019; 286: 1-6.
[http://dx.doi.org/10.1016/j.ijcard.2019.03.059] [PMID: 30952529]
[38]
Devereux RB, Roman MJ. Inter-relationships between hypertension, left ventricular hypertrophy and coronary heart disease. J Hypertens 1993; 11(4) (Suppl. 4): S3-S10.
[http://dx.doi.org/10.1097/00004872-199306003-00003] [PMID: 8377033]
[39]
Huang B, Yang L, Yang B, et al. Relationship of body fat and left ventricular hypertrophy with the risk of all-cause death in patients with coronary artery disease. J Geriatr Cardiol 2022; 19(3): 218-26.
[http://dx.doi.org/10.11909/j.issn.1671-5411.2022.03.002]
[40]
Choi YJ, Park JB, Park CS, et al. Prognostic implications of left ventricular mass-geometry in patients with no or nonobstructive coronary artery disease. BMC Cardiovasc Disord 2021; 21(1): 187.
[http://dx.doi.org/10.1186/s12872-021-02005-6] [PMID: 33858344]
[41]
Kim YH, Her AY, Choi BG, et al. Impact of left ventricular hypertrophy on long-term clinical outcomes in hypertensive patients who underwent successful percutaneous coronary intervention with drug-eluting stents. Medicine (Baltimore) 2018; 97(35): e12067.
[http://dx.doi.org/10.1097/MD.0000000000012067] [PMID: 30170421]
[42]
Park JS, Shin JS, Lee YH, et al. Left ventricular hypertrophy on long-term cardiovascular outcomes in patients with ST-elevation myocardial infarction. Clin Exp Hypertens 2015; 37(8): 674-9.
[http://dx.doi.org/10.3109/10641963.2015.1047943] [PMID: 26151825]
[43]
Yildiz M, Oktay AA, Stewart MH, Milani RV, Ventura HO, Lavie CJ. Left ventricular hypertrophy and hypertension. Prog Cardiovasc Dis 2020; 63(1): 10-21.
[http://dx.doi.org/10.1016/j.pcad.2019.11.009] [PMID: 31759953]
[44]
East MA, Jollis JG, Nelson CL, Marks D, Peterson ED. The influence of left ventricular hypertrophyon survival in patients with coronaryartery disease: do race and gender matter? J Am Coll Cardiol 2003; 41(6): 949-54.
[http://dx.doi.org/10.1016/S0735-1097(02)03006-1] [PMID: 12651039]
[45]
Ang D, Pringle S, Struthers A. The cardiovascular risk factor, left ventricular hypertrophy, is highly prevalent in stable, treated angina pectoris. Am J Hypertens 2007; 20(10): 1029-35.
[http://dx.doi.org/10.1016/j.amjhyper.2007.04.021] [PMID: 17903683]
[46]
Zabalgoitia M, Berning J, Koren MJ, et al. Impact of coronary artery disease on left ventricular systolic function and geometry in hypertensive patients with left ventricular hypertrophy (the LIFE study). Am J Cardiol 2001; 88(6): 646-50.
[http://dx.doi.org/10.1016/S0002-9149(01)01807-0] [PMID: 11564388]
[47]
Walpot J, Massalha S, Hossain A, et al. Left ventricular mass is independently related to coronary artery atherosclerotic burden. J Thorac Imaging 2021; 36(3): 181-8.
[http://dx.doi.org/10.1097/RTI.0000000000000511] [PMID: 32251235]
[48]
Ford TJ, Howden N. "Vessels of Vessels". JACC Cardiovasc Interv 2021; 14(6): 619-22.
[http://dx.doi.org/10.1016/j.jcin.2021.02.007] [PMID: 33736769]
[49]
Anderson T. Re-examination of some of the Framingham blood-pressure data. Lancet 1978; 312(8100): 1139-41.
[http://dx.doi.org/10.1016/S0140-6736(78)92288-2] [PMID: 82694]
[50]
Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-52.
[http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2] [PMID: 14656957]
[51]
Sanchez RA, Ayala M, Baglivo H, et al. Latin American Expert Group. Latin American guidelines on hypertension. J Hypertens 2009; 27(5): 905-22.
[http://dx.doi.org/10.1097/HJH.0b013e32832aa6d2] [PMID: 19349909]
[52]
van den Born BJ, Beutler JJ, Gaillard CA, de Gooijer A, van den Meiracker AH, Kroon AA. Dutch guideline for the management of hypertensive crisis -- 2010 revision. Neth J Med 2011; 69(5): 248-55.
[PMID: 21646675]
[53]
Aronow WS, Fleg JL, Pepine CJ, et al. ACCF Task Force. Circulation 2011; 123(21): 2434-506.
[http://dx.doi.org/10.1161/CIR.0b013e31821daaf6] [PMID: 21518977]
[54]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J 2013; 34(28): 2159-219.
[http://dx.doi.org/10.1093/eurheartj/eht151] [PMID: 23771844]
[55]
Wolf SJ, Lo B, Shih RD, Smith MD, Fesmire FM. American College of Emergency Physicians Clinical Policies Committee. Clinical policy: critical issues in the evaluation and management of adult patients in the emergency department with asymptomatic elevated blood pressure. Ann Emerg Med 2013; 62(1): 59-68.
[http://dx.doi.org/10.1016/j.annemergmed.2013.05.012] [PMID: 23842053]
[56]
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311(5): 507-20.
[http://dx.doi.org/10.1001/jama.2013.284427] [PMID: 24352797]
[57]
Seedat YK, Rayner BL, Veriava Y. Hypertension guideline working group. South African hypertension practice guideline 2014: review article. Cardiovasc J Afr 2014; 25(6): 288-94.
[http://dx.doi.org/10.5830/CVJA-2014-062] [PMID: 25629715]
[58]
Gabb GM, Mangoni AA, Anderson CS, et al. Guideline for the diagnosis and management of hypertension in adults - 2016. Med J Aust 2016; 205(2): 85-9.
[http://dx.doi.org/10.5694/mja16.00526] [PMID: 27456450]
[59]
Malachias MVB, Barbosa ECD, Martim JF, Rosito GBA, Toledo JY, Passarelli O. 7th Brazilian guideline of arterial hypertension: Chapter 14 - Hypertensive Crisis. Arq Bras Cardiol 2016; 107 (Suppl. 3): 79-83.
[PMID: 27819393]
[60]
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018; 138(17): e426-83.
[PMID: 30354655]
[61]
Nyanjau L, Gathecha G, Maree E, Nato J, Bukachi F, Gitura B. Kenya national guidelines for cardiovascular diseases management. Developed by the Division of Non-Communicable Diseases Ministry of Health 2018 Available from: www.health.go.ke [cited: 20 June 2021].
[62]
SESLHD Hypertension policy development working party. Management of Hypertension in the SESLHD Ward Settings. South Eastern Sydney Local Health District Guideline. SESLHDGL/068. 2018. Available from: https://www.seslhd.health.nsw.gov.au/sites/default/files/documents/SESLHDGL068.pdf [cited: 20 June 2021].
[63]
Joint Committee for Guideline Revision. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. J Geriatr Cardiol 2019; 16(3): 182-241.
[PMID: 31080465]
[64]
Academy of Medicine of Malaysia. The Clinical Practice Guidelines (CPGs); Management of hypertension 5th Ed . 2018. Available from: http://www.acadmed.org.my/ index.cfm?menuid=67
[65]
van den Born BJH, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother 2019; 5(1): 37-46.
[http://dx.doi.org/10.1093/ehjcvp/pvy032] [PMID: 30165588]
[66]
Umemura S, Arima H, Arima S, et al. The Japanese Society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res 2019; 42(9): 1235-481.
[http://dx.doi.org/10.1038/s41440-019-0284-9] [PMID: 31375757]
[67]
Hua Q, Fan L, Li J. Joint Committee for Guideline Revision. 2019 Chinese guideline for the management of hypertension in the elderly. J Geriatr Cardiol 2019; 16(2): 67-99.
[PMID: 30923539]
[68]
Vilela-Martin JF, Yugar-Toledo JC, Rodrigues MC, et al. Luso-Brazilian position statement on hypertensive emergencies - 2020. Arq Bras Cardiol 2020; 114(4): 736-51.
[http://dx.doi.org/10.36660/abc.20190731] [PMID: 32491016]
[69]
Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada’s 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol 2020; 36(5): 596-624.
[http://dx.doi.org/10.1016/j.cjca.2020.02.086] [PMID: 32389335]
[70]
Tschanz CMP, Cushman WC, Harrell CTE, Berlowitz DR, Sall JL. Synopsis of the 2020 U.S. Department of Veterans Affairs/U.S. Department of defense clinical practice guideline: The diagnosis and management of hypertension in the primary care setting. Ann Intern Med 2020; 173(11): 904-13.
[http://dx.doi.org/10.7326/M20-3798] [PMID: 32866417]
[71]
Pathak A, Mrabeti S. β-blockade for patients with hypertension, ischemic heart disease or heart failure: Where are we now? Vasc Health Risk Manag 2021; 17: 337-48.
[http://dx.doi.org/10.2147/VHRM.S285907] [PMID: 34135591]
[72]
Rosendorff C, Lackland DT, Allison M, et al. American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Circulation 2015; 131(19): e435-70.
[http://dx.doi.org/10.1161/CIR.0000000000000207] [PMID: 25829340]
[73]
Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020; 41(3): 407-77.
[http://dx.doi.org/10.1093/eurheartj/ehz425] [PMID: 31504439]
[74]
Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American college of cardiology foundation/American heart association task force on practice guidelines, and the American college of physicians, American association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol 2012; 60(24): e44-e164.
[http://dx.doi.org/10.1016/j.jacc.2012.07.013] [PMID: 23182125]
[75]
Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J 2013; 34(38): 2949-3003.
[http://dx.doi.org/10.1093/eurheartj/eht296] [PMID: 23996286]
[76]
National Institute for Health and Care Excellence. Stable Angina: Management. Clinical guideline [CG126]. NICE 2011 Available from: https://www.nice.org.uk/guidance/cg126
[77]
Mancini GBJ, Gosselin G, Chow B, et al. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol 2014; 30(8): 837-49.
[http://dx.doi.org/10.1016/j.cjca.2014.05.013] [PMID: 25064578]
[78]
Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2018; 39(2): 119-77.
[http://dx.doi.org/10.1093/eurheartj/ehx393] [PMID: 28886621]
[79]
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130(25): e344-426.
[PMID: 25249585]
[80]
O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2013; 127(4): e362-425.
[http://dx.doi.org/10.1161/CIR.0b013e3182742c84] [PMID: 23247304]
[81]
Koraćević GP, Dakić SS, Veličković-Radovanović RM, et al. Amlodipine as an antiischemic drug is superior to long acting nitrates. Open Med (Wars) 2014; 10(1): 50-6.
[PMID: 28352677]
[82]
Bornstein AB, Rao SS, Marwaha K. Left Ventricular Hypertrophy. Treasure Island, FL: StatPearls Publishing 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/32491466/.
[83]
Kunadian V, Chieffo A, Camici PG, et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur Heart J 2020; 41(37): 3504-20.
[http://dx.doi.org/10.1093/eurheartj/ehaa503] [PMID: 32626906]
[84]
Bairey Merz CN, Pepine CJ, Walsh MN, et al. Ischemia and No Obstructive Coronary Artery Disease (INOCA). Circulation 2017; 135(11): 1075-92.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.024534] [PMID: 28289007]
[85]
Pacheco Claudio C, Quesada O, Pepine CJ, Noel Bairey Merz C. Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive coronary artery disease). Clin Cardiol 2018; 41(2): 185-93.
[http://dx.doi.org/10.1002/clc.22894] [PMID: 29498752]
[86]
Khalid K, Padda J, Ismail D, et al. Correlation of coronary artery disease and left ventricular hypertrophy. Cureus 2021; 13(8): e17550.
[http://dx.doi.org/10.7759/cureus.17550] [PMID: 34646607]
[87]
Angeli F, Verdecchia P, Trapasso M, Reboldi G. Left ventricular hypertrophy and coronary artery calcifications: A dangerous duet? Am J Hypertens 2018; 31(3): 287-9.
[http://dx.doi.org/10.1093/ajh/hpx192] [PMID: 29136095]
[88]
Sun J, Liu X, Zhang Q, Zhang Q. Study on the correlation between Left Ventricular Hypertrophy and Coronary Artery disease in the very elderly patients with hypertension. Pak J Med Sci 2021; 37(5): 1382-6.
[http://dx.doi.org/10.12669/pjms.37.5.4135] [PMID: 34475916]
[89]
Guo C, Yang W, Dong M, et al. Myocardial blood flow decreases in hypertensive patients with non-obstructive epicardial coronary stenosis: New evidence provided by dynamic stress CT myocardial perfusion imaging. Clin Surg 2021; 6: 3170.
[90]
Sun N, Chen JW, Wang J, et al. Asian expert consensus for the diagnosis and treatment of hypertension-associated left ventricular hypertrophy. Cardiology Plus 2016; 1(3): 37-47.
[http://dx.doi.org/10.4103/2470-7511.248356]
[91]
Vancheri F, Longo G, Vancheri S, Henein M. Coronary microvascular dysfunction. J Clin Med 2020; 9(9): 2880.
[http://dx.doi.org/10.3390/jcm9092880] [PMID: 32899944]
[92]
Nadarajah R, Patel PA, Tayebjee MH. Is hypertensive left ventricular hypertrophy a cause of sustained ventricular arrhythmias in humans? J Hum Hypertens 2021; 35(6): 492-8.
[http://dx.doi.org/10.1038/s41371-021-00503-w] [PMID: 33674703]
[93]
Koracevic G, Micic S, Stojanovic M. By discontinuing beta-blockers before an exercise test, we may precipitate a rebound phenomenon. Curr Vasc Pharmacol 2021; 19(6): 624-33.
[http://dx.doi.org/10.2174/1570161119666210302152322] [PMID: 33653252]
[94]
Santucci A, Riccini C, Cavallini C. Treatment of stable ischaemic heart disease: the old and the new. Eur Heart J Suppl 2020; 22 (Suppl. E): E54-9.
[http://dx.doi.org/10.1093/eurheartj/suaa060] [PMID: 32523440]
[95]
Boyette LC, Manna B. Physiology, Myocardial Oxygen Demand Treasure Island, FL: StatPearls Publishing 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/29763072/
[96]
Udom GJ, Effiong DE, Onyeukwu NJ, Obot DN, Alozie M, Yemitan OK. Recent trends in the pharmacotherapy of angina pectoris. IOSR J Pharm 2020; 10(5): 01-13.
[97]
Kawel-Boehm N, Kronmal R, Eng J, et al. Left ventricular mass at mri and long-term risk of cardiovascular events: The multi-ethnic study of Atherosclerosis (MESA). Radiology 2019; 293(1): 107-14.
[http://dx.doi.org/10.1148/radiol.2019182871] [PMID: 31453766]
[98]
Egan BM, Kjeldsen SE, Grassi G, Esler M, Mancia G. The global burden of hypertension exceeds 1.4 billion people. J Hypertens 2019; 37(6): 1148-53.
[http://dx.doi.org/10.1097/HJH.0000000000002021] [PMID: 30624370]
[99]
Nadar SK, Lip GYH. The heart in hypertension. J Hum Hypertens 2021; 35(5): 383-6.
[http://dx.doi.org/10.1038/s41371-020-00427-x] [PMID: 33046827]
[100]
Giamouzis G, Dimos A, Xanthopoulos A, Skoularigis J, Triposkiadis F. Left ventricular hypertrophy and sudden cardiac death. Heart Fail Rev 2022; 27(2): 711-24.
[http://dx.doi.org/10.1007/s10741-021-10134-5] [PMID: 34184173]
[101]
Feng YT, Feng XF. Sudden cardiac death in patients with myocardial infarction: 1.5 primary prevention. Rev Cardiovasc Med 2021; 22(3): 807-16.
[http://dx.doi.org/10.31083/j.rcm2203087] [PMID: 34565079]

Rights & Permissions Print Cite
Article Metrics
28
2
© 2024 Bentham Science Publishers | Privacy Policy